Literature DB >> 16627591

Amphotericin B tissue distribution in autopsy material after treatment with liposomal amphotericin B and amphotericin B colloidal dispersion.

Helene Vogelsinger1, Stefan Weiler, Angela Djanani, Jordan Kountchev, Rosa Bellmann-Weiler, Christian J Wiedermann, Romuald Bellmann.   

Abstract

OBJECTIVES: Tissue concentrations of amphotericin B were determined in autopsy material of patients who had been treated with liposomal amphotericin B or amphotericin B colloidal dispersion (colloidal amphotericin B) for suspected or proven invasive fungal infection. PATIENTS AND METHODS: Amphotericin B tissue levels were measured in liver, spleen, lung, kidney, and myocardial and brain tissue of 20 patients who had been treated with lipid-formulated amphotericin B, before they died from multi-organ failure. Seven patients had been treated with liposomal amphotericin B (AmBisome) and thirteen with colloidal amphotericin B (Amphocil). Tissue samples were obtained during routine autopsy, homogenized and extracted with methanol. Amphotericin B concentrations were measured using HPLC after purification by solid phase extraction.
RESULTS: The highest amphotericin B levels were found in liver and spleen, followed by kidney, lung, myocardium and brain. In the lung higher amphotericin B concentrations were found after treatment with amphotericin B colloidal dispersion than after therapy with liposomal amphotericin B.
CONCLUSIONS: The choice of lipid formulation may influence amphotericin B penetration into the lung.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16627591     DOI: 10.1093/jac/dkl141

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  42 in total

1.  Can we use a lower dose of liposomal amphotericin B for the treatment of mucosal American leishmaniasis?

Authors:  Valdir S Amato; Felipe F Tuon; Raphael A Camargo; Regina M Souza; Carolina R Santos; Antonio C Nicodemo
Journal:  Am J Trop Med Hyg       Date:  2011-11       Impact factor: 2.345

2.  Human tissue distribution of voriconazole.

Authors:  Stefan Weiler; David Fiegl; Róisín MacFarland; Eva Stienecke; Rosa Bellmann-Weiler; Stefan Dunzendorfer; Michael Joannidis; Romuald Bellmann
Journal:  Antimicrob Agents Chemother       Date:  2010-11-15       Impact factor: 5.191

3.  In Vitro and In Vivo Exposure-Effect Relationship of Liposomal Amphotericin B against Aspergillus fumigatus.

Authors:  Maria Siopi; Johan W Mouton; Spyros Pournaras; Joseph Meletiadis
Journal:  Antimicrob Agents Chemother       Date:  2019-05-24       Impact factor: 5.191

Review 4.  Pharmacokinetics of antifungal drugs: practical implications for optimized treatment of patients.

Authors:  Romuald Bellmann; Piotr Smuszkiewicz
Journal:  Infection       Date:  2017-07-12       Impact factor: 3.553

Review 5.  Beyond tissue concentrations: antifungal penetration at the site of infection.

Authors:  Yanan Zhao; Brendan Prideaux; Shane Baistrocchi; Donald C Sheppard; David S Perlin
Journal:  Med Mycol       Date:  2019-04-01       Impact factor: 4.076

6.  Short-course High-dose Liposomal Amphotericin B for Human Immunodeficiency Virus-associated Cryptococcal Meningitis: A Phase 2 Randomized Controlled Trial.

Authors:  Joseph N Jarvis; Tshepo B Leeme; Mooketsi Molefi; Awilly A Chofle; Gabriella Bidwell; Katlego Tsholo; Nametso Tlhako; Norah Mawoko; Raju K K Patel; Mark W Tenforde; Charles Muthoga; Gregory P Bisson; Jeremiah Kidola; John Changalucha; David Lawrence; Shabbar Jaffar; William Hope; Si le F Molloy; Thomas S Harrison
Journal:  Clin Infect Dis       Date:  2019-01-18       Impact factor: 9.079

Review 7.  Therapeutic Challenges of Non-Aspergillus Invasive Mold Infections in Immunosuppressed Patients.

Authors:  Frederic Lamoth; Dimitrios P Kontoyiannis
Journal:  Antimicrob Agents Chemother       Date:  2019-10-22       Impact factor: 5.191

8.  The Added Value of Longitudinal Imaging for Preclinical In Vivo Efficacy Testing of Therapeutic Compounds against Cerebral Cryptococcosis.

Authors:  Greetje Vande Velde; Uwe Himmelreich; Liesbeth Vanherp; Jennifer Poelmans; Amy Hillen; Guilhem Janbon; Matthias Brock; Katrien Lagrou
Journal:  Antimicrob Agents Chemother       Date:  2020-06-23       Impact factor: 5.191

9.  Aerosolized Delivery of Antifungal Agents.

Authors:  Jennifer Le; Daryl S Schiller
Journal:  Curr Fungal Infect Rep       Date:  2010-04-13

Review 10.  Liposomal amphotericin B: a review of its use as empirical therapy in febrile neutropenia and in the treatment of invasive fungal infections.

Authors:  Marit D Moen; Katherine A Lyseng-Williamson; Lesley J Scott
Journal:  Drugs       Date:  2009       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.